Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Translational Neurodegeneration
Published in: Translational Neurodegeneration 1/2018

Open Access 01-12-2018 | Research

Cognitive characteristics in Chinese non-demented PD patients based on gender difference

Authors: Ke Yang, Bo Shen, Da-ke Li, Ying Wang, Jue Zhao, Jian Zhao, Wen-Bo Yu, Zhen-yang Liu, Yi-lin Tang, Feng-tao Liu, Huan Yu, Jian Wang, Qi-hao Guo, Jian-jun Wu

Published in: Translational Neurodegeneration | Issue 1/2018

Login to get access

Abstract

Background

Cognitive impairment is one of the non-motor symptoms in Parkinson’s disease (PD). In the present study, we aim to examine the cognitive function of non-demented Parkinson’s disease patients and compare the results between male and female patients as well as control groups in search of any gender effect.

Methods

Sixty PD Patients (30 males and 30 females) from the Movement Disorders Clinic at Huashan Hospital Affiliated to Fudan University were recruited to participate in the study. One hundred age and gender matched control subjects without neurological or psychiatric disorders were voluntarily recruited. The participants were administered measures of cognition in five domains including memory, language, spatial processing abilities, attention and executive function.

Results

PD patients attained significantly lower scores in the visual spatial function, language and attention/executive function compared with the control group. Anti-parkinsonian treated patients performed worse in Rey-copy score, Clock Drawing Test (CDT) and Verbal Fluency-City than untreated ones. In regard to gender differences, though no general cognitive differences were found in Mini-mental State Examination (MMSE), men surpassed women on Boston naming test (BNT) while women were superior on Auditory Verbal Learning Test-long (AVLT) delayed cued recall test.

Conclusions

Cognitive impairments were common in PD patients even in the absence of dementia. PD patients with anti-parkinsonian medication had worse cognitive impairment than untreated patients. Genders may have different manifestations of cognitive impairment in PD patients.
Literature
1.
Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry. 2000;69(3):308–12.CrossRefPubMedPubMedCentral
2.
Muslimovic D, et al. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005;65(8):1239–45.CrossRefPubMed
3.
Aarsland D, Bronnick K, Fladby T. Mild cognitive impairment in Parkinson's disease. Curr Neurol Neurosci Rep. 2011;11(4):371–8.CrossRefPubMed
4.
Aarsland D, et al. Risk of dementia in Parkinson's disease: a community-based, prospective study. Neurology. 2001;56(6):730–6.CrossRefPubMed
5.
Allain H, et al. Procedural memory and Parkinson's disease. Dementia. 1995;6(3):174–8.PubMed
6.
Brown RG, Marsden CD. Cognitive function in Parkinson's disease: from description to theory. Trends Neurosci. 1990;13(1):21–9.CrossRefPubMed
7.
Dluzen DE, McDermott JL. Gender differences in neurotoxicity of the nigrostriatal dopaminergic system: implications for Parkinson’s disease. J Gend Specif Med. 2000;3(6):36–42.PubMed
8.
Van Den Eeden SK, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157(11):1015–22.CrossRefPubMed
9.
Lyons KE, et al. Gender differences in Parkinson’s disease. Clin Neuropharmacol. 1998;21(2):118–21.PubMed
10.
Braak H, et al. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology. 2005;64(8):1404–10.CrossRefPubMed
11.
Nazem S, et al. Montreal cognitive assessment performance in patients with Parkinson’s disease with “normal” global cognition according to mini-mental state examination score. J Am Geriatr Soc. 2009;57(2):304–8.CrossRefPubMed
12.
Riedel O, et al. Cognitive impairment in 873 patients with idiopathic Parkinson’s disease. Results from the German study on epidemiology of Parkinson’s disease with dementia (GEPAD). J Neurol. 2008;255(2):255–64.CrossRefPubMed
13.
MacDonald AA, et al. Differential effects of Parkinson's disease and dopamine replacement on memory encoding and retrieval. PLoS One. 2013;8(9):e74044.CrossRefPubMedPubMedCentral
14.
Edelstyn NM, et al. Effect of disease severity and dopaminergic medication on recollection and familiarity in patients with idiopathic nondementing Parkinson’s. Neuropsychologia. 2010;48(5):1367–75.CrossRefPubMed
15.
Hanna-Pladdy B, Pahwa R, Lyons KE. Paradoxical effect of dopamine medication on cognition in Parkinson’s disease: relationship to side of motor onset. J Int Neuropsychol Soc. 2015;21(4):259–70.CrossRefPubMedPubMedCentral
16.
Daniel SE, Lees AJ. Parkinson’s disease society brain Bank, London: overview and research. J Neural Transm Suppl. 1993;39:165–72.PubMed
17.
Runeson BS, Rich CL. Diagnostic and statistical manual of mental disorders, 3rd ed. (DSM-III), adaptive functioning in young Swedish suicides. Ann Clin Psychiatry. 1994;6(3):181–3.CrossRefPubMed
18.
19.
Goetz CG, et al. Movement Disorder Society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–70.CrossRefPubMed
20.
Tomlinson CL, et al. Systematic review of levodopa dose equivalency reporting in Parkinson’s disease. Mov Disord. 2010;25(15):2649–53.CrossRefPubMed
21.
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.CrossRefPubMed
22.
Higginson CI, et al. The relationship between executive function and verbal memory in Parkinson’s disease. Brain Cogn. 2003;52(3):343–52.CrossRefPubMed
23.
Cormack F, et al. Pentagon drawing and neuropsychological performance in dementia with Lewy bodies, Alzheimer’s disease, Parkinson’s disease and Parkinson’s disease with dementia. Int J Geriatr Psychiatry. 2004;19(4):371–7.CrossRefPubMed
24.
O'Brien TJ, et al. The contribution of executive control on verbal-learning impairment in patients with Parkinson’s disease with dementia and Alzheimer’s disease. Arch Clin Neuropsychol. 2009;24(3):237–44.CrossRefPubMedPubMedCentral
25.
Tomer R, Levin BE, Weiner WJ. Side of onset of motor symptoms influences cognition in Parkinson’s disease. Ann Neurol. 1993;34(4):579–84.CrossRefPubMed
26.
Locascio JJ, Corkin S, Growdon JH. Relation between clinical characteristics of Parkinson's disease and cognitive decline. J Clin Exp Neuropsychol. 2003;25(1):94–109.CrossRefPubMed
27.
Solla P, et al. Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson’s disease. J Neurol Sci. 2012;323(1–2):33–9.CrossRefPubMed
28.
Green J, et al. Cognitive impairments in advanced PD without dementia. Neurology. 2002;59(9):1320–4.CrossRefPubMed
29.
Balthazar ML, et al. Learning, retrieval, and recognition are compromised in aMCI and mild AD: are distinct episodic memory processes mediated by the same anatomical structures? J Int Neuropsychol Soc. 2010;16(1):205–9.CrossRefPubMed
30.
Zec RF, et al. A cross-sectional study of the effects of age, education, and gender on the Boston naming test. Clin Neuropsychol. 2007;21(4):587–616.CrossRefPubMed
31.
32.
Gatto NM, et al. Lifetime exposure to estrogens and Parkinson’s disease in California teachers. Parkinsonism Relat Disord. 2014;20(11):1149–56.CrossRefPubMed
33.
Liu B, Dluzen DE. Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson’s disease. Clin Exp Pharmacol Physiol. 2007;34(7):555–65.CrossRefPubMed
34.
Janowsky JS. The role of androgens in cognition and brain aging in men. Neuroscience. 2006;138(3):1015–20.CrossRefPubMed
35.
Stern Y. What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc. 2002;8(3):448–60.CrossRefPubMed
36.
Barnes LL, et al. Gender, cognitive decline, and risk of AD in older persons. Neurology. 2003;60(11):1777–81.CrossRefPubMed
37.
Beinhoff U, et al. Gender-specificities in Alzheimer’s disease and mild cognitive impairment. J Neurol. 2008;255(1):117–22.CrossRefPubMed
38.
Ripich DN, et al. Gender differences in language of AD patients: a longitudinal study. Neurology. 1995;45(2):299–302.CrossRefPubMed
39.
Volf NV, Razumnikova OM. Sex differences in EEG coherence during a verbal memory task in normal adults. Int J Psychophysiol. 1999;34(2):113–22.CrossRefPubMed
40.
Clements AM, et al. Sex differences in cerebral laterality of language and visuospatial processing. Brain Lang. 2006;98(2):150–8.CrossRefPubMed
41.
Antonova E, et al. The relationship between brain structure and neurocognition in schizophrenia: a selective review. Schizophr Res. 2004;70(2–3):117–45.CrossRefPubMed
42.
Gur RC, et al. An fMRI study of sex differences in regional activation to a verbal and a spatial task. Brain Lang. 2000;74(2):157–70.CrossRefPubMed
43.
Proust-Lima C, et al. Gender and education impact on brain aging: a general cognitive factor approach. Psychol Aging. 2008;23(3):608–20.CrossRefPubMed
44.
45.
Guo Q, et al. A comparison study of mild cognitive impairment with 3 memory tests among Chinese individuals. Alzheimer Dis Assoc Disord. 2009;23(3):253–9.CrossRefPubMed
46.
Caffarra P, et al. Rey-Osterrieth complex figure: normative values in an Italian population sample. Neurol Sci. 2002;22(6):443–7.CrossRefPubMed
47.
Guo Q, Fu J, Yuan J, et al. A study of validity of a new scoring system of clock drawing test. Chin J Neurol. 2008;41(4):234–7.
48.
Lucas JA, et al. Mayo’s older African Americans normative studies: norms for Boston naming test, controlled oral word association, category fluency, animal naming, token test, WRAT-3 reading, trail making test, Stroop test, and judgment of line orientation. Clin Neuropsychol. 2005;19(2):243–69.CrossRefPubMed
49.
50.
Steinberg BA, et al. Mayo’s older Americans normative studies: age- and IQ-adjusted norms for the trail-making test, the Stroop test, and MAE controlled oral word association test. Clin Neuropsychol. 2005;19(3–4):329–77.CrossRefPubMed
Metadata
Title
Cognitive characteristics in Chinese non-demented PD patients based on gender difference
Authors
Ke Yang
Bo Shen
Da-ke Li
Ying Wang
Jue Zhao
Jian Zhao
Wen-Bo Yu
Zhen-yang Liu
Yi-lin Tang
Feng-tao Liu
Huan Yu
Jian Wang
Qi-hao Guo
Jian-jun Wu
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Translational Neurodegeneration / Issue 1/2018
Electronic ISSN: 2047-9158
DOI
https://doi.org/10.1186/s40035-018-0120-1

Other articles of this Issue 1/2018

Translational Neurodegeneration 1/2018 Go to the issue

Review

Hydrogen sulfide, nitric oxide, and neurodegenerative disorders

Correction

Correction to: Alterations of brain local functional connectivity in amnestic mild cognitive impairment

Research

AGE-induced neuronal cell death is enhanced in G2019S LRRK2 mutation with increased RAGE expression

Research

Dopaminergic neurons show increased low-molecular-mass protein 7 activity induced by 6-hydroxydopamine in vitro and in vivo

Research

Ultra-High Field Diffusion MRI Reveals Early Axonal Pathology in Spinal Cord of ALS mice

Review

Factors that influence adult neurogenesis as potential therapy